Back to search results

Exercise Intervention for Primary Antibody Deficiency Disorders

This study is testing an App-based exercise intervention, a 12-week structured moderate-intensity exercise program delivered through a mobile app. It aims to see if this program is safe, practical, and acceptable for adults with primary antibody deficiency disorders (conditions where your body doesn't make enough antibodies to fight infections). The study also wants to find out if the program can improve your quality of life and help your immune system work better. You can join if you are 18 to 65 years old, have a diagnosed primary antibody deficiency (like IgG subclass deficiency, selective IgA deficiency, selective IgM deficiency, or specific antibody deficiency), are receiving care in the Section of Rheumatology, Allergy & Immunology, and are willing to do moderate exercise. The study will measure how many people join, how many stay in the study for 12 weeks, and how often they use the app. The current recruitment status is unclear.

Study design
This is an interventional study with a planned enrollment of 20 participants. The phase of the study is not specified.
What's involved
You will complete health questionnaires, participate in a 12-week exercise program using a mobile app, have your exercise activity tracked, report symptoms or infections, and provide blood samples at patient visits. Assessments will be done at the beginning and end of the study.
Compensation
Not stated in the trial record.
Follow-up
The study measures retention and app usage at 12 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07698197

Exercise Intervention and Immunodeficiency

Recruiting
NAAges 18–65InterventionalTreatment
Yale University
~20 participants
Updated 2026-07-23 on ClinicalTrials.gov
What's tested:App-based exercise intervention

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Recruitment rate
Measured over Day 1
+5 more outcomes measured

Conditions

Primary Antibody Deficiency Disorders

Explore related trials

Immunoglobulin G subclass deficiencySelective IgE ImmunodeficiencySpecific antibody deficiency

Where it's being run

2 sites across 1 states
Connecticut2

Study leadership

  • Ryan Steele, DO, MSc · PRINCIPAL_INVESTIGATOR · Yale University

Who to contact

Ryan Steele, DO, MSc
[email protected]
203-785-7092 · ext. 57092
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosed with one of the following primary antibody deficiencies: IgG subclass deficiency, selective IgA deficiency, selective IgM deficiency, or specific antibody deficiency
Receiving care in the Section of Rheumatology, Allergy \& Immunology
Able and willing to participate in a moderate-intensity exercise program. Patients will be screened using the American College of Sports Medicine (ACSM) Pre- participation Screening Guidelines. This algorithm assesses patients for cardiovascular, renal, and metabolic disease. Those patients determined to not require further medical clearance to participate in exercise will be included.

Exclusion

Receipt of immunoglobulin (Ig) replacement therapy
Use of immunosuppressive or immunomodulatory medications (e.g., chronic systemic corticosteroids, B-cell-depleting therapies)
Medical contraindications to moderate-intensity exercise as determined by clinical assessment using the previously discussed ACSM Pre-participation Screening Guidelines.
Other risk factors/medical conditions that would limit safe participation in exercise as determined by clinical assessment, including active rheumatologic conditions including active rheumatoid arthritis.

What this trial measures

  • Recruitment rateDay 1

    Number and proportion of eligible individuals who enroll

  • Retention rate12 weeks

    Number of enrolled participants who complete the 12-week study

  • Frequency of app usage- Adherence12 weeks

    Mean number of times app was utilized

  • Duration of workout- Adherence12 weeks

    Mean duration of workout in minutes

  • Mean score Borg Scale of Rating of Perceived Exertion12 weeks

    Measures exertion on a total scale of 0 (no exertion or resting) to 10 (pushing yourself to the max).

  • Data completeness12 weeks

    Proportion of expected study data successfully collected at each time point